Hair loss breakthrough? supplement shows promise in new study
NCT ID NCT07111312
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This 6-month study tested a daily drinkable supplement containing vitamins, minerals, and plant extracts in 106 women aged 18-40 with telogen effluvium (a common temporary hair loss). Half took the supplement, half took a placebo. Researchers measured hair density and growth cycle changes using scalp imaging. The goal was to see if the supplement could safely improve hair health.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- a drinkable supplement with vitamins, minerals, and plant extracts
- What this could lead to
- If it works, this could offer a natural option to help women with temporary hair loss regrow thicker hair.
- What could go wrong
- This is a small, completed study with 106 women. The supplement is not a drug, so effects may be modest. Results may not apply to all types of hair loss.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
106 people
The number who actually took part.
- Started
-
Oct 2023
- Finished
-
Sep 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 40 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age: 18-40 years * Sex: female * Telogen effluvium diagnosis with hair loss \> 100 hairs, confirmed using validated "modified wash test" * Otherwise, healthy volunteers * Refraining from systemic, topical, oral products with similar effects to the active product * Signed informed consent * Maintenance of daily cosmetic and dietary routine * Availability to attend all visits * Compliance with all protocol requirements Exclusion Criteria: * Previous use of active product * Participation in similar studies or usage of anti-hair loss products within the last 3 months * History of dermatological treatment (e.g. mesotherapy) and/or hair transplant * Skin or scalp diseases (e.g. psoriasis, dermatitis, alopecias) * Alopecia secondary to medical diseases (e.g. hypothyroidism, anemia) * Ongoing treatment for or diagnosis of systemic disease * Hormonal treatment (oral or topical contraceptives) within 6 months prior to study start * Known allergy or intolerance, including to any of the ingredients of the active product * Pregnancy, post-partum (6 months) or breastfeeding
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Telogen effluvium are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clínica AB Derma
Madrid, Spain
-
Zurko-CTC
Barcelona, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.